Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy is prescribed as a once-weekly injection, and that weekly schedule is not simply a convenience — it is central to how semaglutide works in the body. Taking Wegovy every two weeks rather than every seven days is not how the medicine is licensed or clinically designed, and doing so is likely to reduce its effectiveness. As a prescription-only medicine, the dosing schedule is set by your prescriber based on the licensed guidance; any changes should go through them, not through trial and error at home. The NHS semaglutide medicines page covers the approved schedule in full, and it is worth reading before adjusting anything.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It's a question our prescribers hear regularly, and it usually comes from a reasonable place: supply has been patchy, or the monthly cost feels steep, and doubling the interval looks like a tidy solution. The honest answer is that the weekly schedule exists for a clinical reason, not a commercial one.
Semaglutide has what pharmacologists call a long half-life (roughly one week) which is why once-weekly dosing keeps blood levels in a therapeutically useful range. Inject every two weeks instead and the concentration in your system drops significantly in the second week. Appetite suppression, the main driver of the weight-management benefit, fades with it. For most people this means more hunger, more difficulty with portion control, and a slower rate of progress than the trial data would suggest.
The NHS guidance on semaglutide is clear that the prescribed schedule should be followed. If you find yourself tempted to stretch doses, that is a signal worth raising with whoever is looking after your treatment, not something to solve quietly by changing the interval yourself. You can read more about how semaglutide works as a medicine on our semaglutide overview page.
Wegovy starts at a low dose precisely because the GI side effects) nausea, loose stools, that unsettled stomach feeling in the first couple of weeks, are real and worth managing carefully. The titration schedule (0.25mg for four weeks, then 0.5mg, then 1.0mg, then 1.7mg, reaching 2.4mg as the maintenance dose) is designed to let your body adjust at each rung before moving up.
Spreading doses to every two weeks does not meaningfully replicate that graduated process. What it does instead is create an irregular cycle of adequate and inadequate drug levels, which may also make the GI side effects less predictable. The benefit of dose escalation is a relatively stable plasma level at each step, bi-weekly dosing undermines that stability.
There is also a separate question about what to do if you genuinely miss a dose. The Patient Information Leaflet (available via the electronic Medicines Compendium) gives specific guidance on this: if fewer than five days have passed since your scheduled dose, take it as soon as possible; if it has been five or more days, skip that dose and resume on your usual day. That is very different from deliberately adopting a fortnightly schedule.
If you are curious about what happens with other interval variations, we've covered the evidence around taking Wegovy every six days and the question of dosing every ten days in separate pages.
Supply of Wegovy has been genuinely inconsistent in parts of the UK, and cost is a legitimate concern. These are the two most common reasons people search for information about taking Wegovy every 2 weeks, and neither of them is solved well by halving the dose frequency.
If cost is the issue, our Wegovy cost context page explains what legitimate private treatment includes and what headline prices sometimes leave out, it's a more useful frame than comparing per-pen prices in isolation. For supply concerns, the right conversation is with your prescriber, who can document supply interruptions and advise on the safest approach to gaps.
If you are on a 1.7mg or 2.4mg maintenance dose and your pen simply did not arrive in time, taking the next one a few days late is a different situation from planning a fortnightly schedule. Again, the PIL and your prescriber are the authoritative sources for what to do in that circumstance, not an adjusted regime decided at home.
Some people also ask whether a lower, more affordable dose taken weekly might be preferable to a higher dose every two weeks. That is genuinely a clinical conversation, one a GPhC-registered prescriber can have with you based on your health picture, not one with a clean general answer. Our Wegovy overview covers the licensed doses and what each stage of the schedule is designed to do.
If you want to understand the full landscape of Wegovy access, including how private treatment compares to NHS pathways, the routes to getting Wegovy page is a practical starting point. And if you're at the stage of weighing up whether treatment is right for you at all, our weight-loss treatment overview sets out the options clearly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.